Skip to Content

Wilate Approval History

FDA Approved: Yes (First approved December 4, 2009)
Brand name: Wilate
Generic name: von Willebrand Factor/Coagulation Factor VIII Complex (Human)
Dosage form: Injection
Company: Octapharma USA
Treatment for: von Willebrand's Disease

Wilate is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD).

Development History and FDA Approval Process for Wilate

DateArticle
Dec  8, 2009Approval Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide